Teleflex - TFX Stock Forecast, Price & News

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Teleflex Stock Performance

TFX traded down $3.79 during midday trading on Friday, reaching $241.66. The company had a trading volume of 4,022 shares, compared to its average volume of 550,804. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.43 and a current ratio of 2.27. The stock has a market cap of $11.33 billion, a PE ratio of 22.47, a P/E/G ratio of 2.41 and a beta of 1.10. Teleflex has a 12-month low of $235.01 and a 12-month high of $405.89. The business has a 50-day moving average price of $252.58 and a two-hundred day moving average price of $294.68.

Teleflex (NYSE:TFX - Get Rating) last released its earnings results on Thursday, July 28th. The medical technology company reported $3.39 earnings per share for the quarter, beating analysts' consensus estimates of $3.34 by $0.05. Teleflex had a net margin of 18.16% and a return on equity of 16.84%. The firm had revenue of $704.50 million for the quarter, compared to analysts' expectations of $719.50 million. During the same period in the previous year, the company earned $3.35 earnings per share. The company's quarterly revenue was down 1.3% on a year-over-year basis. On average, sell-side analysts expect that Teleflex will post 13.16 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Monday, August 15th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.56%. The ex-dividend date of this dividend is Friday, August 12th. Teleflex's dividend payout ratio (DPR) is currently 12.64%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on TFX shares. Piper Sandler lowered their target price on shares of Teleflex from $295.00 to $265.00 in a research note on Thursday, July 28th. StockNews.com downgraded shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. Morgan Stanley decreased their price target on shares of Teleflex from $300.00 to $278.00 and set an "equal weight" rating for the company in a research note on Friday, July 29th. TheStreet downgraded shares of Teleflex from a "b-" rating to a "c+" rating in a research note on Monday, May 16th. Finally, Bank of America assumed coverage on shares of Teleflex in a research note on Monday, May 9th. They issued a "neutral" rating and a $315.00 price target for the company. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $340.09.

Insider Activity

In other news, Director Stuart A. Randle sold 3,014 shares of the business's stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $283.31, for a total value of $853,896.34. Following the sale, the director now owns 4,320 shares of the company's stock, valued at $1,223,899.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.28% of the company's stock.